InfraReDx (Burlington, Massachusetts) is testing out a hypothesis in its CANARY (Coronary Assessment by Near-infrared (NIR) of Atherosclerotic Rupture-prone Yellow) trial that could prove beneficial in reducing the rate of peri-procedural heart attacks in patients identified as having high-risk lipid core plaques. (Medical Device Daily) Read More
